The efficacy of chemotherapy might be more limited in patients with ESCC; therefore, therapeutic approaches, including those utilizing ICIs, might be more challenging in patients with high serum anti-p53 antibody levels [9]. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.